warfarin and carbamazepine

Carbamazepine induces hepatic cytochrome P450 enzymes, particularly CYP2C9 and CYP3A4, which are involved in the metabolism of warfarin. Induction increases warfarin clearance, leading to lower plasma concentrations and reduced anticoagulant effect.

The anticoagulant effect of warfarin is reduced, potentially resulting in subtherapeutic INR and an increased risk of thromboembolic events such as stroke or deep vein thrombosis. The effect is clinically significant when carbamazepine is initiated or discontinued, and the extent of enzyme induction varies between patients.

Monitor INR closely, typically within 3 to 5 days of starting or stopping carbamazepine, and adjust the warfarin dose accordingly. Consider an alternative antiepileptic that does not induce hepatic enzymes if possible. Advise patients to report signs of thrombosis or bleeding. When carbamazepine is stopped, the warfarin dose will likely need to be reduced to avoid excessive anticoagulation.

Well-established interaction, supported by numerous case reports and pharmacokinetic studies. Carbamazepine is a known enzyme inducer, and the interaction with warfarin is predictable and documented in standard reference sources and prescribing information.